Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Novartis’s Gilenya Given Final Approval by U.K.’s Cost Agency

April 25 (Bloomberg) -- Novartis AG’s multiple sclerosis pill Gilenya won final approval from England’s health-cost agency for some patients after the company agreed to a discounted price.

The National Institute for Health and Clinical Excellence, or NICE, recommended Gilenya as a treatment option for some adults with relapsing-remitting multiple sclerosis, a form of the disease in which symptoms worsen and improve periodically, it said in a statement today. The decision confirms a preliminary ruling made last month.

Gilenya costs about 19,196 pounds ($30,970). NICE isn’t disclosing the size of the discount that Novartis offered.

To contact the reporter on this story: Phil Serafino in Paris at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.